J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront
17 Apr 2023
Phase 1PROTACs
Johnson & Johnson’s Janssen unit is delving into the muscarinic space with $50 million upfront for an oral Pipeline Therapeutics asset that will enter a Phase II in the second half of this year, CEO and president Carmine Stengone told
Endpoints News
.
The San Diego biotech tested its investigational compound, the muscarinic M1 antagonist PIPE-307, in
two
Phase I
studies
and has gained an FDA go-ahead for a mid-stage study in patients with relapsing-remitting multiple sclerosis, or RRMS. After the Phase I studies showed a “clean
safety profile
,” Pipeline attracted “a fair bit of partnering interest,” with a few term sheets negotiated during the process, Stengone said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.